Current investors


CM-CIC Innovation is a subsidiary of CM-CIC Investissement specialized in venture capital investments. Its objective is to invest in companies developing promising technologies. CM-CIC Innovation selects companies with strong growth potential in dynamic sectors such as information technologies, telecommunications, electronics, life sciences, new materials or the environment. The policy of CM-CIC Innovation is to provide support with long-term capital to innovative startups to streamline their chances of success.


Remiges Ventures is a US-based cross-border venture capital firm with close connections to the Japanese pharmaceutical industry having two major pharmaceutical companies in Japan as limited partners. Remiges has a strong focus on drug discovery and development and invests in early stage companies having promising drug candidates based on disruptive science. Remiges’ goal is to support entrepreneurs to develop innovative therapeutics that help patients suffering from diseases.


GO CAPITAL is a venture capital firm managing more than €190 million, invested in more than 70 innovative technology companies in the West of France. The fund GO CAPITAL Amorçage was created with the support of the French State-owned seed Fund (Fonds National d’Amorçage, FNA), managed by bpifrance’s Future Investments Programme, the European Investment Fund, the regions of Bretagne, Pays de la Loire and Normandie, and banking partners Crédit Mutuel Arkea and Crédit Agricole. GO CAPITAL, through its funds GO CAPITAL Amorçage and Ouest Ventures, has made investments in about thirty companies in the areas of Digital, Health and Energy Transition.


Participations Besançon is a family company headed by Mr. and Mrs. Pierre Besançon, head-quartered in Paris, France. Its primary investments are in listed and unlisted French pharmaceutical and biotech companies.